PubRank

Vittorio Bertele'

Author PubWeight™ 22.70‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Non-inferiority trials are unethical because they disregard patients' interests. Lancet 2007 4.72
2 Europe's opportunity to open up drug regulation. BMJ 2010 1.71
3 Disappointing biotech. BMJ 2005 1.66
4 Ethics in clinical research. J Hepatol 2009 1.54
5 Anything new in EU pharmacovigilance? Eur J Clin Pharmacol 2011 1.53
6 Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol 2012 1.39
7 Efficacy, safety and cost of new drugs acting on the central nervous system. Eur J Clin Pharmacol 2003 1.11
8 Efficacy, safety and cost of new cardiovascular drugs: a survey. Eur J Clin Pharmacol 2003 1.10
9 Enhancing the rational use of new medicines across European health care systems. Eur J Clin Pharmacol 2008 0.99
10 How can we regulate medicines better? BMJ 2007 0.98
11 A failed attempt at collaboration. BMJ 2013 0.92
12 Rosiglitazone and the need for a new drug safety agency. BMJ 2010 0.80
13 Bevacizumab and ranibizumab. A matter of public interest. BMJ 2010 0.77
14 Exenatide for type 2 diabetes. Lancet 2009 0.75
15 Dutasteride and prostate cancer. N Engl J Med 2010 0.75
16 Antibiotics versus surgery for appendicitis. Lancet 2011 0.75
17 Alternative medical practices: flashbacks from the Dark Ages. Eur J Intern Med 2010 0.75
18 Informed consent: meet patients' needs. Nature 2012 0.75
19 [False innovations in clinical research]. Recenti Prog Med 2006 0.75
20 Toward new legislation on drugs in Europe. Expert Rev Pharmacoecon Outcomes Res 2002 0.75
21 European Council waters down European Parliament's drug-regulatory legislation. Lancet 2003 0.75
22 Light and shade in proposed revision of EU drug-regulatory legislation. Lancet 2003 0.75
23 The impact of European regulatory policies on psychotropic drug prescribing patterns. Int Rev Psychiatry 2005 0.75
24 Do we learn the right things from clinical trials? Eur J Clin Pharmacol 2008 0.75
25 Limits of add-on trials: antirheumatic drugs. Eur J Clin Pharmacol 2008 0.75
26 The European Commission should require better medicines, not just faster reimbursements. Eur J Intern Med 2012 0.75
27 The scientific community should lobby to be able to apply for drug licences. BMJ 2012 0.75